| |
|
|
Drug name
|
Condition |
Division |
| Abraxane® (paclitaxel protein-bound particles) |
Oncology
|
Accredo Nova Factor
|
Actimmune® (interferon gamma-1b)
|
Immune Deficiency
|
Accredo Therapeutics |
Adagen® (pegademase bovine)
|
Severe Combined Immunodeficiency (SCID)
|
Accredo Nova Factor |
Advate® (antihemophilic factor [recombinant])
|
Hemophilia/Bleeding Disorders
|
Hemophilia Health Services |
Aldurazyme® (laronidase)
|
Mucopolysaccharidosis
|
Accredo Therapeutics |
Alphanate® (antihemophilic factor [human])
|
Hemophilia/Bleeding Disorders
|
Hemophilia Health Services |
AlphaNine® SD (coagulation factor IX [human])
|
Hemophilia/Bleeding Disorders
|
Hemophilia Health Services |
Amevive® (alefacept)
|
Psoriasis
|
Accredo Nova Factor |
| Amicar® (aminocaproic acid) |
Hemophilia/Bleeding Disorders
|
Hemophilia Health Services |
Apokyn® (apomorphine hydrochloride)
|
Parkinson’s
|
Accredo Nova Factor |
Aralast® (alpha[1]-proteinase inhibitor [human])
|
Alpha-1 Antitrypsin Deficiency
|
Accredo Therapeutics |
Aranesp® (darbepoetin alfa)
|
Anemia/Neutropenia
|
Accredo Nova Factor |
Arcalyst®
|
Cryopyrin-Associates Periodic Syndromes (CAPS)
|
Accredo Nova Factor |
Arixtra® (fondaparinux sodium)
|
DVT/Anticoagulation
|
Accredo Nova Factor |
Arranon® (nelarabine)
|
Oncology
|
Accredo Nova Factor |
Avastin® (bevacizumab)
|
Oncology
|
Accredo Nova Factor |
| Avonex® (interferon beta-1a) |
Multiple Sclerosis |
Accredo Nova Factor |